President-elect Donald Trump announced his intention to 'knock out the middleman' in the pharmaceutical industry, referring to pharmacy benefit managers (PBMs). He stated his goal is to significantly reduce drug costs.
UnitedHealth Group's Optum division controls a substantial portion of the U.S. pharmacy benefit market. Trump's comments suggest a potential for significant regulatory changes that could impact the business model of PBMs.
This declaration by the President-elect signals a period of heightened political scrutiny and potential reform for companies operating PBMs. The stated aim is to achieve drug costs at levels 'nobody has ever seen before.'
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.